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Dear Editor
Eliciting Eosinophil CCR3 Expression by
Synthetic Retinoids
Over the past several decades, information about the
mechanisms of eosinophilic inflammation has been
accumulating. Eosinophils in tissue are supplied by
blood because they are terminally differentiated, non-
dividing cells. Eosinophils that accumulate at sites of
inflammation contribute to tissue injury, vascular
leakage, mucus secretion, and tissue remodeling by
releasing their cytotoxic granule proteins, reactive
oxygen species (ROS), and lipid mediators.1 A seven
transmembrane-spanning G-coupled receptor, CCR3,
is selectively expressed on eosinophils and plays an
important role in the trafficking of eosinophils from
circulation to tissue both in healthy individuals and
those with allergic reactions.
Retinoids are natural and synthetic analogues of vi-
tamin A. In a series in our previous study, we found
that naturally occurring retinoids, retinoic acids
( RAs ), elicit CCR 3 expression on human blood
eosinophils. 2 Peripheral blood eosinophils constitu-
tively express nuclear receptors for retinoids, RA re-
ceptor (RAR)-α, -β, and -γ, and retinoid X receptor
(RXR)-α and -β.3 Using a gene microarray, we have
screened up-regulation of CCR3 transcription in RA-
stimulated eosinophils. Indeed, RAs have a significant
effect on inducing cell surface expression of CCR3 on
eosinophils. Furthermore, RA-induced CCR3 leads to
enhanced functional capacities in terms of calcium
signaling and chemotactic responses. 2 Surprisingly,
RAs are the first recognized physiological CCR3 up-
regulator in mature human eosinophils despite the
recent progress in eosinophil biology.
It has been known that RAs play critical roles in
mucosal immunity, especially modulating tissue-
specific lymphocyte homing. Vitamin A deficiency de-
creases the number of T and B cells in the small
bowel lamina propria.4 Gut-associated lymphoid
tissue-resident dendritic cells produce RAs that in-
duce the gut homing receptors including CCR9 on
lymphocytes. In this context, locally produced RAs
might contribute to up-regulation of CCR3 on eosino-
phils to support the migration to gut mucosa where
they normally reside.
To date, retinoids have been used for treatment of
patients with skin diseases and acute promyelocytic
leukemia. Many synthetic retinoids have been re-
ported, the majority of which have a therapeutic pur-
pose. To study whether synthetic retinoids have a
similar effect on eosinophils, we obtained several
compounds and tested their effect on CCR3 expres-
sion. Eosinophils were purified by negative selection
using anti-CD16 immunomagnetic beads (MACS Sys-
tem, Miltenyi Biotec, Bergisch Gladbach, Germany)
as previously described.3 The experimental settings
followed our prior study. Cells were incubated at 0.5
× 106 cellsml in 10% fetal calf serum containing
RPMI 1640 medium with indicated synthetic reti-
noids or vehicle. Since RAs affect eosinophil survival,
the culture duration (18 hrs) was carefully chosen
based on a prior study. 2 Nonpermeabilized eosino-
phils were stained with FITC-conjugated anti-human
CCR 3 monoclonal antibody or isotype-matched
mouse IgG control antibody (DACO), followed by
measurement of CCR3 expression using a FACScan
flow cytometer. The effects of synthetic retinoids
were studied at the concentration of 10−7 M, which is
applied to the optimal concentration for 9-cisRA.2
Among the six synthetic retinoids we tested, Am80
(also called tamibarotene), IT-compounds (a kind gift
from Dr. K. Shudo, Itsuu Laboratory, Tokyo, Japan),5
and Ch55 up-regulated CCR3 expression (Table1).
The flow cytometric histograms indicated that the
whole population of eosinophils responded to in-
creased CCR3 expression induced by synthetic reti-
noids (Am80: Fig.1). As shown in the Table 1, a po-
tent effect was observed in Am80-stimulated cells.
Am80 is a RAR-α and β agonist that was originally de-
signed to ameliorate the side effect of RAs through its
potent and more selective binding to RAR-α,6 the acti-
vation of which is indispensable for CCR 3 up-
regulation on eosinophils. To support our previous
notion that RXR partially compensates for the effect
of RAs, a slight effect of pan-RXR agonist methoprene
acid was observed. These results indicate that syn-
thetic retinoids (RAR agonists) have a similar effect
to natural retinoids, eliciting CCR3 expression on hu-
man eosinophils.
Therapeutic use of retinoids is potentially associ-
ated with inflammatory adverse effects such as reti-
noic acid syndrome and inflammatory bowel disease.7
The accumulation of eosinophils in the gastrointesti-
nal tract is a common feature of numerous gastroin-
testinal diseases, including inflammatory bowel dis-
ease.1 Our data may be important in understanding
the mechanisms of the clinical effects of synthetic ret-
inoids and future drug discovery targeting eosino-
philic inflammation. It is noteworthy that eosino-
philiopoeisis appears to be under complex control of
RAs under physiological conditions; RAs have pleiot-
ropic effects on eosinophils according to the stage of
cell differentiation. For instance, RAs inhibit the
eosinophil differentiation in progenitor cells 8 and
eosinophilic cell lines9,10; however, they prevent the
spontaneous apoptosis of mature eosinophils. 3 Fur-
ther studies are required to define the relevance of
retinoid administration on eosinophil functions in
vivo.
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Fig.　1　The effect of Am80 on CCR3 expression on blood-
derived human eosinophils. Purifi ed eosinophils were incu-
bated with vehicle or 10−7 M Am80 for 18 hrs. Representative 
histograms of fl ow cytometric analysis for surface CCR3 ex-
pression are shown (fi lled histograms: baseline expression in 
vehicle-treated control cells, open histograms: Am80-stimulated 
cells).
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Table　1　The effect of synthetic retinoids on CCR3 expression on eosinophils
Retinoids (10−7 M) Am80 IT-YA-01115 IT-M-01500 IT-YA-01201 Ch55 Methoprene acid
Activity RARα/β agonist RARα/β agonist RARα/β agonist RARα/β agonist pan-RAR agonist pan-RXR agonist
CCR3 expression 
(% of control ± SD) 142.1 ± 16.7** 136.8 ± 23.7** 138.9 ± 23.2** 137.5 ± 22.9** 125.1 ± 13.1* 121.6 ± 27.7
Data were assessed by the ratio of mean fl uorescence intensity of the sample and the isotype-matched control, non-stimulated control 
normalized % values. Results were expressed as mean ± SD (n = 4-6, different donors). Differences of groups were evaluated using two-
tailed Student’s t-test. **p < 0.01, *p < 0.05 vs. control.
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